AVXL Anavex Life Sciences
- 3.990
- +0.180+4.72%
- 3.930
- -0.060-1.50%
Anavex Life Sciences News
Anavex Life Sciences Corp. (NASDAQ:AVXL) Q2 2024 Earnings Call Transcript
Express News | HC Wainwright & Co. Reiterates Buy on Anavex Life Sciences, Maintains $40 Price Target
Anavex Life Sciences Analyst Ratings
Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/10/2024 938.96% HC Wainwright & Co. → $40 Reiterates Buy → Buy 01/03/2024 938.96% HC Wainwright & Co. $
Express News | Anavex Life Sciences Corp : Jonestrading Cuts Target Price to $15
Anavex Life Sciences | 10-Q: Quarterly report
Buy Rating on Anavex Life Sciences Amid Promising Alzheimer's Drug Prospects
Anavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call Transcript
Anavex Life Sciences Corp. (AVXL) Q2 2024 Earnings Call Transcript
Express News | Anavex Life Sciences Q2 2024 GAAP EPS $(0.13) Misses $(0.11) Estimate, Cash and Equivalents of $139.4M
Press Release: Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update Company to host a webcast today at 8:30 a.m. Eastern Time NEW YORK, May 09, 2024 (GLOBE NEWSWIR
Anavex Life Sciences 2Q Loss/Shr 13c >AVXL
Anavex Life Sciences 2Q Loss/Shr 13c >AVXL
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
NEW YORK, May 02, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
NEW YORK, April 11, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
Companies Like Anavex Life Sciences (NASDAQ:AVXL) Are In A Position To Invest In Growth
Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the right price. For example, biotech and mining exploration companies often lose mo
Anavex Life Sciences(AVXL.US) Officer Sells US$374.97K in Common Stock
$Anavex Life Sciences(AVXL.US)$ Officer MISSLING CHRISTOPHER U sold 73,380 shares of Common Stock on Mar 28, 2024 at an average price of $5.11 for a total value of $374.97K.Source: Announcement What i
Form 144 | Anavex Life Sciences(AVXL.US) Officer Proposes to Sell 371.3K in Common Stocks
SEC FILLINGS DISCLOSED/ Mar 28, $Anavex Life Sciences(AVXL.US)$ Officer MISSLING CHRISTOPHER U intends to sell 73,380 shares of its common stock on Mar 28, with a total market value of approximately $
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
NEW YORK, March 25, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
Express News | Anavex Life Sciences Announced That The First Patient In Its Phase 2 Study Of ANAVEX3-71 For Schizophrenia Has Been Screened Ahead Of Schedule
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX3-71 in Schizophrenia
First patient screened ahead of schedule Trial to investigate positive, negative, and cognitive domains of schizophrenia ANAVEX3-71's differentiated dual novel mechanism of action offers the potential to
AVLX, SGH and ETNB Are Among Pre Market Losers
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
NEW YORK, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (NASDAQ:AVXL), a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of
Analysis
Price Target
No Data
